GIST: Assessment of Tumor Mutations and TKI Plasma Exposure

Plain-language summary

This study examined tumor mutations and blood levels of the drug in patients diagnosed with gastrointestinal stromal tumor (GIST) who were planned for tyrosine kinase inhibitor (TKI) treatment. Participants provided a blood sample and a tumor biopsy. It was a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Medical Center Groningen

Intervention

Vena puncture for blood collection, Tumor biopsy

Start date

12/8/2014

Estimated completion

1/31/2024

Countries

Netherlands

Related genes

Locations

• Amsterdam, Netherlands
• Groningen, Netherlands
• Leiden, Netherlands
• Nijmegen, Netherlands
• Rotterdam, Netherlands

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients diagnosed with a GIST with an indication to be treated with a TKI of whom a histological biopsy before start treatment is available.
* Informed consent is given

Exclusion Criteria:

* Patients of whom no tumor is available before start of first line TKI
* Patients that refuse a tumor biopsy in case of tumor progression
* Patients in whom it will not be possible to perform a biopsy in case of tumor progression (for example anti-coagulants that cannot be interrupted).